Maxim Group Forecasts Strong Price Appreciation for Sensus Healthcare (NASDAQ:SRTS) Stock

Sensus Healthcare (NASDAQ:SRTS) had its target price boosted by Maxim Group from $12.00 to $14.00 in a report published on Friday, Marketbeat Ratings reports. The firm currently has a buy rating on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Sensus Healthcare in a research note on Monday, August 12th.

Sensus Healthcare Price Performance

NASDAQ:SRTS opened at $8.41 on Friday. The firm has a market cap of $137.83 million, a price-to-earnings ratio of 14.60 and a beta of 1.04. The firm’s fifty day moving average price is $6.37 and its 200 day moving average price is $5.97. Sensus Healthcare has a 1-year low of $2.02 and a 1-year high of $8.69.

Institutional Investors Weigh In On Sensus Healthcare

A number of institutional investors and hedge funds have recently modified their holdings of the company. Truvestments Capital LLC purchased a new stake in Sensus Healthcare during the third quarter worth $32,000. Chapin Davis Inc. purchased a new position in Sensus Healthcare during the 2nd quarter valued at about $53,000. XTX Topco Ltd acquired a new position in Sensus Healthcare during the second quarter worth about $95,000. Hillsdale Investment Management Inc. acquired a new stake in shares of Sensus Healthcare in the first quarter valued at approximately $155,000. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Sensus Healthcare during the 2nd quarter worth approximately $156,000. Institutional investors and hedge funds own 25.30% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.